Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CU-T12-9 是特异性 TLR1/2激动剂,可激活先天免疫系统和适应性免疫系统。它选择性激活 TLR1/2 异二聚体,可通过促进 TLR1 和 TLR2 二聚而激活 NF-κB 信号,引起下游 TNF-α、IL-10 和 iNOS 增加。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 415 | 现货 | ||
2 mg | ¥ 596 | 现货 | ||
5 mg | ¥ 898 | 现货 | ||
10 mg | ¥ 1,490 | 现货 | ||
25 mg | ¥ 2,680 | 现货 | ||
50 mg | ¥ 3,920 | 现货 | ||
100 mg | ¥ 5,690 | 现货 | ||
500 mg | ¥ 11,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 937 | 现货 |
产品描述 | CU-T12-9 is a potent TLR1/2 agonist(EC50 of 52.9 nM in HEK-Blue hTLR2 SEAP assay). It acts by activating the NFkB pathway, upregulating proinflammatory cytokines, and enhancing TLR1 and TLR2 dimerization.CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 selectively activates the TLR1/2 heterodimer, not TLR2/6. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS. |
靶点活性 | TLR2:52.9 nM (EC50)(in HEK-Blue cells), TLR1:52.9 nM (EC50)(in HEK-Blue cells) |
体外活性 |
CU-T12-9 directly targets TLR1/2 to initiate downstream signaling.?CU-T12-9 specifically induces TLR1/2 activation, which can be blocked by either the anti-hTLR1 or the anti-hTLR2 antibody, but not the anti-hTLR6 antibody.?By binding to both TLR1 and TLR2, CU-T12-9 facilitates the TLR1/2 heterodimeric complex formation, which in turn activates the downstream signaling.?Fluorescence anisotropy assays revealed competitive binding to the TLR1/2 complex between CU-T12-9 and Pam3CSK4 with a half-maximal inhibitory concentration (IC50) of 54.4 nM.?CU-T12-9 signals through nuclear factor κB (NF-κB) and invokes an elevation of the downstream effectors tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), and inducible nitric oxide synthase (iNOS)[1].? |
分子量 | 362.31 |
分子式 | C17H13F3N4O2 |
CAS No. | 1821387-73-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (690.02 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.7601 mL | 13.8003 mL | 27.6007 mL | 69.0017 mL |
5 mM | 0.552 mL | 2.7601 mL | 5.5201 mL | 13.8003 mL | |
10 mM | 0.276 mL | 1.38 mL | 2.7601 mL | 6.9002 mL | |
20 mM | 0.138 mL | 0.69 mL | 1.38 mL | 3.4501 mL | |
50 mM | 0.0552 mL | 0.276 mL | 0.552 mL | 1.38 mL | |
100 mM | 0.0276 mL | 0.138 mL | 0.276 mL | 0.69 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CU-T12-9 1821387-73-8 Immunology/Inflammation TLR obesity inflammatory carcinoma cancer Toll-like Receptor (TLR) TLR1/2 diseases specific infectious bladder CU-T-12-9 CUT129 Inhibitor breast asthma CU T12 9 inhibit influenza pancreatic inhibitor